# US 2025/0084356 A1 · Physiologically-relevant, serum-free in vitro angiogenesis platform > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2025/0084356 A1 - Document ID: US20250084356A1 - Status: Published application - Kind: A1 - Application number: 18/725,006 - Filed: 2023-01-06 - Published: 2025-03-13 - Earliest claimed: 2022-01-07 - Assignees: South Dakota Board of Regents - Applicants: South Dakota Board of Regents - Inventors: Laura A.E. Brunmaier; Travis W. Walker; Cyle Miller; Timothy M. Brenza - Web page: https://patentgrep.com/patent/US20250084356A1 ## CPC - C12M 21/08: {for producing artificial tissue or for ex-vivo cultivation of tissue (prostheses A61F2/00, grafts A61L27/00)} - C12M 23/12: {Well or multiwell plates (C12M25/04 takes precedence)} - C12M 25/14: {Scaffolds; Matrices (in general C12N5/0068)} - C12M 29/00: {Means for introduction, extraction or recirculation of materials, e.g. pumps (pumps per se F04B)} - C12M 29/10: {Perfusion} - C12M 41/14: {Incubators; Climatic chambers (per se B01L1/00)} - C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS} ## Abstract A custom platform is developed that is capable of culturing endothelial cells three-dimensionally while inducing physiological stimuli on the cells. A model includes serum-free conditions, allowing more quantifiable angiogenesis studies that investigate the dose dependent effects of various growth factors. Angiogenesis plays a critical role during development, wound healing, and disease; therefore, further investigation of the pathway has broad implications. Also, the development of in vitro vascularized tissue models via angiogenesis provides the ability to investigate endothelial responses after exposure to nanoparticles and mechanisms of drug delivery. ## Claims ### Claim 1 A physiologically-relevant, serum-free in vitro angiogenesis platform, comprising: a cell chamber; one or more perfusable channels disposed within the cell chamber; one or more ports in a sidewall of the cell chamber; a track operably disposed on at least one side of the cell chamber, and at least one connector disposed in the track, the at least one connector configured for introducing one or more concentrations of nanoparticles into the cell chamber. ### Claim 2 (depends on 1) The platform of claim 1, further comprising: a slip operably configured for housing the cell chamber. ### Claim 3 (depends on 2) The platform of claim 2, wherein the slip comprises the one or more ports. ### Claim 4 (depends on 1) The platform of claim 1, wherein the perfusable channels comprise hydrogel walls. ### Claim 5 (depends on 1) The platform of claim 1, further comprising: one or more syringes for introducing the one or more concentrations of nanoparticles. ### Claim 6 (depends on 5) The platform of claim 5, wherein the syringe is operably locked by the at least one connector disposed on the track. ### Claim 7 (depends on 6) The platform of claim 6, wherein the syringe is inserted into a hydrogel in the cell chamber by adjusting the position of the track. ### Claim 8 (depends on 5) The platform of claim 5, wherein the syringe is retracted from a hydrogel in the cell chamber by adjusting the position of the track. ### Claim 9 A system for a physiologically-relevant, serum-free in vitro angiogenesis platform, comprising: an incubator operably configured for housing a cell media; a peristaltic pump for moving the cell media; a microscope for conducting microscopy of the cell media; and a cell chamber having one or more perfusable channels, a viewing window for observation with the microscope, and one or more ports in a sidewall of the cell chamber for introducing one or more concentrations of nanoparticles; wherein endothelial cells line the one or more perfusable channels. ### Claim 10 (depends on 9) The system of claim 9, further comprising a slip having one or more ports in operable communication with the one or more ports in the sidewall of the cell chamber. ### Claim 11 (depends on 10) The system of claim 10, further comprising: one or more syringes for introducing the one or more concentrations of nanoparticles. ### Claim 12 (depends on 10) The system of claim 10, further comprising: a track operably disposed on at least one side of the cell chamber. ### Claim 13 (depends on 12) The system of claim 12, further comprising: at least one connector disposed in the track, the at least one connector configured for introducing one or more concentrations of nanoparticles into the cell chamber. ### Claim 14 (depends on 10) The system of claim 10, wherein the syringe is adjusted in position relative to the cell media in the cell chamber by adjusting the position of the track. ### Claim 15 A method for physiologically-relevant, serum-free in vitro angiogenesis, comprising: providing a cell chamber having one or more perfusable channels, a viewing window for microscopy observation, and one or more ports in a sidewall of the cell chamber; introducing cell media into the cell chamber; introducing one or more concentrations of nanoparticles into the cell chamber via the one or more ports in the sidewall of the cell chamber; and circulating cell media through the cell chamber. ### Claim 16 (depends on 15) The method of claim 15, further comprising: a track operably disposed on at least one side of the cell chamber. ### Claim 17 (depends on 15) The method of claim 15, further comprising: introducing the one or more concentrations of nanoparticles with one or more syringes. ### Claim 18 (depends on 15) The method of claim 15, further comprising: inserting a syringe into a hydrogel in the cell chamber by adjusting the position of a track. ### Claim 19 (depends on 15) The method of claim 15, further comprising: retracting the syringe from a hydrogel in the cell chamber by adjusting the position of the track. ### Claim 20 (depends on 16) The method of claim 16, wherein the track comprises at least one connector configured for introducing one or more concentrations of nanoparticles into the cell chamber.